News
Maintenance of Remission with Tofacitinib in Patients with UC – Results of the OCTAVE Open Study
Tofacitinib is indicated for the treatment of ulcerative colitis (UC) in cases where conventional treatment or monoclonal antibodies do not yield sufficient results. Key benefits of this medication include oral administration and predictable kinetics. The long-term efficacy of tofacitinib was studied in the OCTAVE Open study.
Indication of Bilastine in Specific Patient Groups − Practical Tips for Clinical Practice
Bilastine is a non-sedating H1-antihistamine, which is very well tolerated by patients. It can be…
Bilastine in the treatment of allergic rhinitis – meta-analysis shows advantage of lower somnolence
A newly published systematic review and meta-analysis evaluate the efficacy and safety of bilastine…
Need for Early Intervention in COPD − A Suitable Time for Mucolytic Treatment
Chronic Obstructive Pulmonary Disease (COPD) ranks third among the leading causes of morbidity and…
What Did 3 Years of Data from the Czech National COPD Database Reveal?
In December of last year, the Czech multicenter research database on COPD was completed. This was…
COPD is Treated Differently Across Europe – What Could Be the Reasons for This Variability?
As part of this year's Hradec Pneumological Days (HPD 2022), the head of the Pulmonary Clinic at…
Prolonged Course of Metastatic Stomach Cancer with Long-term Stabilization – Case Report
In the following case report, we present the case of a patient with a prolonged oncological disease…
Focused on MS: Statistics Are Boring, But They Have Valuable Data!
What is the prevalence of multiple sclerosis? Has the proportion of patients treated with highly…
Epstein-Barr Virus – Is the Culprit of MS Revealed?
Could the Epstein-Barr virus hold the answer to the etiology of multiple sclerosis? A dataset of…
From Biomarker Testing to NSCLC Treatment Selection
During a satellite symposium at this year's European Lung Cancer Congress (ELCC 2022), Prof. Martin…